Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
10.97
+0.44 (4.18%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
54
Market Cap
685.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 400.05M |
| CytomX Therapeutics | 35.54M |
| Omeros | 9.89M |
| Oculis Holding AG | 1.40M |
| Allogene Therapeutics | 22.00K |
DSGN News
- 10 days ago - Design Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 27 days ago - Design Therapeutics Transcript: Status update - Transcripts
- 27 days ago - Design Therapeutics Press release: Status update - Filings
- 27 days ago - Design Therapeutics Slides: Status update - Filings
- 27 days ago - Design Therapeutics announces biomarker, clinical data from RESTORE-FA trial - TheFly
- 27 days ago - Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia - GlobeNewsWire
- 4 weeks ago - Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026 - GlobeNewsWire